Hospital’s First Coronavirus Patient Discharged After Two Months\n
Get push notifications with news, features and more.Although at this time data is only available for 8 participants — 4 received the lowest dose of the vaccine and 4 received the middle dose — a total of 45 volunteers were enrolled in the initial study, which isTrials for the vaccine — the first to be tested in humans — began in March.
Among participants who received the lowest and middle doses of the vaccine, there was one instance of redness around the injection site; at the highest dose, three participants experienced “transient and self-resolving” adverse events after the second dose, which were not serious. The three subjects experienced fever, muscle pain and headaches, all of which went away after a day, Dr.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Moderna reports 'positive' data on early-stage coronavirus vaccine trial, shares surge 39%Moderna's early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, sending the company's shares surging.
Weiterlesen »
Dow soars more than 700 points, after favorable, early results for coronavirus vaccine candidateU.S. stocks climbed at the start of Monday after drugmaker Moderna announces positive, early results from its first human trial of its experimental Covid-19...
Weiterlesen »
Moderna reports positive data on early-stage coronavirus vaccine trial, shares surgeModerna said its early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all participants, sending its shares surging.
Weiterlesen »
Coronavirus Vaccine Shows ‘Positive’ Early ResultsEight healthy patients who received the vaccine developed antibodies at levels similar to those who’ve recovered from COVID-19.
Weiterlesen »
There are positive early results from Moderna's coronavirus vaccine trialStudy subjects who received Moderna's Covid-19 vaccine had positive early results, according to the biotech company. The results of the study, which was led by the National Institutes Health, haven't been peer reviewed or published in a medical journal.
Weiterlesen »